The company has experienced a total loss of commercial revenue, with growth metrics hitting -100% and quarterly operating losses frequently exceeding $35 million as of 2026Q1.
| Sales/Revenue | 0 | 0 | 87.37M | 380.79M | 22.23M | 0 | 650K | 1.43M |
| Revenue Growth % | 100% | -100% | -77.06% | 1612.94% | - | -100% | -54.42% | - |
| Cost of Goods Sold | 20.2M | 525K | 42.16M | 25.44M | 2.99M | 0 | 24.59M | 11.9M |
| COGS % of Revenue | - | - | 48.25% | 6.68% | 13.46% | - | 3783.69% | 834.43% |
| Gross Profit | -20.2M | -525K | 45.22M | 355.35M | 19.24M | 0 | -23.94M | -10.47M |
| Gross Margin % | - | - | 51.75% | 93.32% | 86.54% | - | -3683.69% | -734.43% |
| Gross Profit Growth % | - | -101.16% | -87.28% | 1747.2% | - | 100% | -128.63% | - |
| Operating Expenses | 139.16M | 152.77M | 359.95M | 316.54M | 220.58M | 82.69M | 15.06M | 13.55M |
| OpEx % of Revenue | - | - | 411.97% | 83.13% | 992.25% | - | 2317.08% | 950.49% |
| Selling, General & Admin | 63.37M | 62.89M | 114.33M | 188.36M | 127.13M | 38.93M | 15.06M | 3.08M |
| SG&A % of Revenue | - | - | 130.86% | 49.47% | 571.88% | - | 2317.08% | 216.06% |
| Research & Development | 95.65M | 90.4M | 104.08M | 128.19M | 93.45M | 44.04M | 24.59M | 11.9M |
| R&D % of Revenue | - | - | 119.13% | 33.66% | 420.38% | - | 3783.69% | 834.43% |
| Other Operating Expenses | -1000K | 0 | 141.53M | 0 | 0 | -285K | -24.59M | -1.43M |
| Operating Income | -159.27M | -153.29M | -314.73M | 38.8M | -201.34M | -82.69M | -39.01M | -13.55M |
| Operating Margin % | - | - | -360.22% | 10.19% | -905.72% | - | -6000.77% | -950.49% |
| Operating Income Growth % | - | 51.29% | -911.12% | 119.27% | -143.49% | -111.99% | -187.77% | - |
| EBITDA | -158.8M | -152.77M | -313.83M | 39.89M | -200.85M | -82.64M | -39M | 0 |
| EBITDA Margin % | - | - | -359.19% | 10.48% | -903.53% | - | -6000.62% | - |
| EBITDA Growth % | 23.21% | 51.32% | -886.73% | 119.86% | -143.06% | -111.87% | - | - |
| D&A (Non-Cash Add-back) | 467K | 525K | 904K | 1.09M | 487K | 52K | 1K | 13.55M |
| EBIT | -150.66M | -144.69M | -291.88M | 38.8M | -201.34M | -82.69M | -39.01M | -12.44M |
| Net Interest Income | 9.64M | 9.3M | 13.81M | 16.16M | 4.29M | 36K | -2.27M | -1.1M |
| Interest Income | 9.64M | 9.3M | 13.81M | 16.16M | 4.29M | 36K | 14K | 176K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 2.29M | 1.28M |
| Other Income/Expense | 9.2M | 8.6M | 12.6M | 15.49M | 3.74M | -5.24M | -3.27M | -162K |
| Pretax Income | -150.07M | -144.69M | -302.14M | 54.3M | -197.6M | -87.93M | -42.28M | -13.72M |
| Pretax Margin % | - | - | -345.81% | 14.26% | -888.89% | - | -6504.62% | -961.85% |
| Income Tax | 46K | 46K | -393K | 5.03M | 774K | 0 | 0 | 0 |
| Effective Tax Rate % | -0.03% | -0.03% | 0.13% | 9.26% | -0.39% | 0% | 0% | 0% |
| Net Income | -150.11M | -144.74M | -301.74M | 49.27M | -198.38M | -87.93M | -42.28M | -14.82M |
| Net Margin % | - | - | -345.36% | 12.94% | -892.38% | - | -6504.62% | -1038.99% |
| Net Income Growth % | 31.41% | 52.03% | -712.41% | 124.84% | -125.6% | -107.97% | -185.37% | - |
| Net Income (Continuing) | -150.11M | -144.74M | -301.74M | 49.27M | -198.38M | -87.93M | -42.28M | -13.72M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.36 | -1.53 | -4.43 | 0.70 | -2.98 | -1.52 | -0.79 | -0.26 |
| EPS Growth % | 52.41% | 65.46% | -732.86% | 123.49% | -96.05% | -92.41% | -203.85% | - |
| EPS (Basic) | - | -1.53 | -4.43 | 0.73 | -2.98 | -1.52 | -0.79 | -0.26 |
| Diluted Shares Outstanding | 110.56M | 94.57M | 68.14M | 69.99M | 66.51M | 57.86M | 56.47M | 56.47M |
| Basic Shares Outstanding | 110.56M | 94.57M | 68.14M | 67.23M | 66.51M | 57.86M | 56.47M | 56.47M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - |
Total loss of revenue
As reported in financial statements, Amylyx has experienced a complete cessation of commercial revenue, with growth metrics hitting -100% following the voluntary withdrawal of Relyvrio, leaving the firm without any active product sales to support its ongoing clinical-stage research and development operations moving forward.
The transition from a commercial-stage entity to a pure-play clinical developer is absolute, as evidenced by the lack of revenue in recent quarters. Investors should note that the company's future growth trajectory is now entirely dependent on the successful regulatory approval of pipeline candidates, which remains highly speculative.
Based on recent quarterly filings, the company maintains a rigid cost structure where R&D expenses consistently range between $20 million and $27 million, reflecting a strategic commitment to clinical trials despite the absence of any offsetting commercial revenue streams to mitigate this ongoing cash burn.
The persistence of high R&D spending suggests that management is prioritizing the advancement of its pipeline over immediate cost-cutting, despite the lack of commercial income. This structure warrants close monitoring, as the company's ability to sustain these expenses without further dilution is increasingly constrained.
According to the income statement data, the company's operating income has remained consistently negative, with quarterly losses frequently exceeding $35 million, indicating that the firm lacks the necessary scale or revenue generation to cover its fixed operating expenses in the current post-commercial environment.
The absence of gross profit means that every dollar spent on SG&A and R&D flows directly to the bottom line as a loss. This lack of operating leverage highlights the extreme risk profile of the firm as it attempts to navigate its next clinical milestones.
As indicated by the persistent quarterly net losses, the company's cash position is being rapidly depleted, raising significant questions about whether the current liquidity will be sufficient to reach critical data readouts without necessitating a dilutive capital raise or a strategic sale of the remaining assets.
While the company holds a cash balance, the burn rate relative to the multi-year timelines for clinical trials suggests that the current financial position may be more precarious than it appears. Investors should be wary of the potential for future financing needs that could significantly impact shareholder value.
Quick answers to the most common questions about buying AMLX stock.
For fiscal year 2025, Amylyx Pharmaceuticals, Inc. (AMLX) reported total revenue of $0.0M. This represents a 100.0% decline compared to $1.4M in 2019.
Amylyx Pharmaceuticals, Inc. (AMLX) reported a net loss of $144.7M for the fiscal year ending 2025.